stella
beta
DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients — Stella
Home
/
HER2-negative Breast Cancer
/
DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients
View on ClinicalTrials.gov
Recruiting
Back to HER2-negative Breast Cancer trials
DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients
Trial locations
(1 site)
United States
Mayo Clinic in Florida, Jacksonville, Florida